VIVEbiotech shares insights on lentiviral vector process validation at CGTP Europe 2026
The company contributed to the scientific programme in Lisbon with a presentation on leveraging prior knowledge to accelerate lentiviral vector process validation for an ultra-orphan autologous cell-based gene therapy.
VIVEbiotech is participating in Cell & Gene Therapy Products Europe 2026 (CGTP Europe 2026), taking place from October 20–22 at the Altis Grand Hotel in Lisbon, Portugal.
As part of the plenary session Innovative Strategies and Tools to Improve CGT Development and Manufacturing, VIVEbiotech contributed with the presentation Leveraging Prior Knowledge to Accelerate Process Validation of a Lentiviral Vector for an Ultra-Orphan Autologous Cell-Based Gene Therapy.
The presentation shared insights from lentiviral vector process validation in the context of an ultra-orphan autologous cell-based gene therapy, highlighting the role that existing knowledge and experience can play in supporting efficient development and manufacturing strategies.
The session was presented by Ana Valero, PhD, Head of Technology Transfer at VIVEbiotech, together with Arjen Scholten from Genewity.
Through its participation in CGTP Europe 2026, VIVEbiotech continues to contribute its experience in lentiviral vector development and manufacturing to scientific and technical discussions within the cell and gene therapies field.
